Chakravarthy comes to Axcella with deep experience in translational medicine, clinical development and therapeutic strategy, and with specific expertise in metabolic diseases.
He will lead Axcella's clinical activities and oversee the execution of clinical studies.
Prior to Axcella, Chakravarthy served as the global head of innovation strategy and external R and D in diabetes and cardiovascular research at Eli Lilly and Co., where he oversaw the identification and evaluation of novel therapeutics and platforms for in/out-licensing, and established academic collaborations to complement and enhance Lilly's internal R and D portfolio.
He additionally served as the industry co-leader of the Innovative Medicine Initiative's LITMUS project, one of the largest public-private consortia efforts to elucidate noninvasive biomarkers for NAFLD.
Before his leadership role at Lilly, Chakravarthy spent more than seven years at Merck and Co., where he assumed positions of increasing responsibility and leadership, ultimately serving as a Distinguished Scientist.
During his tenure at Merck, Chakravarthy spearheaded the design and execution of a variety of clinical trials (mechanistic, biomarker, first-in human, phase 2 POC) in neuroscience, anti-virals, and metabolic diseases.
He also led the Discovery Medicine and Clinical Pharmacology groups within diabetes and cardiometabolic diseases, and oversaw activities that ranged from target identification/validation to studies supporting regulatory filings.
Prior to Merck, Chakravarthy served as an Instructor of Medicine in the Department of Endocrinology and Metabolism at Washington University School of Medicine.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults